Workflow
IoT
icon
搜索文档
CARBIOS enters the r-PET market for tire textile filaments
Globenewswire· 2025-07-21 23:45
CARBIOS has signed a multi-year commercial agreement with Indorama Ventures, the world leader in polyester production. CARBIOS will supply recycled monomers that will be transformed into filaments by Indorama Ventures, intended for use in tire reinforcement for Michelin.This new commercial agreement highlights the interest of a new market—industrial fabrics—for high-quality r-PET derived from enzymatic recycling. Clermont-Ferrand (France), 21 July 2025 (17h45 CEST) – CARBIOS (Euronext Growth Paris: ALCRB) ...
3 Bullish Biotech Stocks With Explosive Growth Trends
MarketBeat· 2025-07-21 23:03
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement. This is particularly true of small-cap biotech stocks. In many cases, these are unprofitable companies with little to no revenue. However, these are also the companies that can provide the highest return for risk-tolerant investors. The risk with these stocks is that the company can deliver poor clinica ...
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
GlobeNewswire News Room· 2025-07-21 23:00
ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. If you purchased shares of Rocket Pharmaceuticals between February 27, 202 ...
Here's Why Repligen (RGEN) is a Strong Growth Stock
ZACKS· 2025-07-21 22:46
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed along ...
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
ZACKS· 2025-07-21 22:41
Key Takeaways VKTX to report Q2 results on July 23 with no revenue expected and a projected EPS loss of $0.44. Investor focus centers on VK2735's VANQUISH trial enrolment and oral dosing study progress. Updates are also expected on IND filing for DACRA obesity candidate and updates on NASH and X-ALD programs.We expect investors to focus on updates related to Viking Therapeutics’ (VKTX) pipeline when it reports second-quarter 2025 results on July 23, after market close. In the last reported quarter, the co ...
Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment
Proactiveinvestors NA· 2025-07-21 21:28
About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Globenewswire· 2025-07-21 21:15
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of MiamiNew patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs)New technology substantially advances Longeveron’s repertoire of stem cell therapy technologiesOpportunity to expand pipeline in cardiovascular, rare a ...
【西街观察】科创板六周年,喜见硬科技上市潮
北京商报· 2025-07-21 21:01
有了资金支持,自然为研发提供了极大支撑,技术攻坚成功率也变得更高。 对于科技企业本身而言,赴港上市是新的出海名片。通过H股上市,接触新的国际客户,加速新技术的 推广和新产品的商业化,提升盈利能力的同时,还能吸引优秀的长期国际投资者,进一步提升企业的投 资价值,实现A、H股的价值共振,降低波动风险。 政策加码,为越来越多科技企业解了燃眉之急。科创板"1+6"新政落地,系统性地解决了科技企业融资 难、信息披露风险高等痛点。在金土地上,高科技含量企业更容易生根发芽。 预先审阅制度,彻底解决了个别高科技企业的上市"焦虑症",硬科技企业上市后备军正加速扩容。 制度包容性不断升级,让一些尚未盈利的硬科技优质企业也有了提前跨进资本市场的可能。生物医药、 人工智能、商业航天等前沿领域的硬科技企业,有机会借助科创板的上市平台,解决融资难的问题。资 本助力之下,它们的科技研发经费更充足,商业化转化来得更快。 7月22日,科创板将迎来开市六周年。从最初的首批25只"星宿股",到现如今的585只,科创板已发展成 中国硬科技企业最大的资本助力场。 科创板是注册制改革的起点,也是资本市场制度改革的"试验田"。如今,注册制改革已由点及面全 ...
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
Forbes· 2025-07-21 21:00
CANADA - 2025/06/08: In this photo illustration, the Sarepta Therapeutics logo is seen displayed on ... More a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesSarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA’s request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlig ...
Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum
Globenewswire· 2025-07-21 20:55
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the BioScience Forum being held July 23, 2025 in San Carlos, CA. Details of the presentation are as follows: Title: Using Logic Gated CARs to Drive Cancer TreatmentSpeaker: Kanya Rajangam, M.D., Ph.D., P ...